or
Remember me
Back
Elixinol Wellness Limited (ASX: EXL / OTC: ELLXF) is expanding CBD market with its diverse product offerings and extensive distribution network. While revenue fell in 2022, EXL's cost-cutting measures reduced G&A expenses and improved EBITDA. New product launches in 2023 are expected to boost revenue.
EXL's acquisition of a hemp company in Australia should increase revenue by 50% and expand EXL's reach into the pet food market. Despite regulatory uncertainty, EXL's strong distribution network and focus on cost reductions make it well-positioned to capitalize on the anticipated growth in the CBD market.
To learn more about EXL's distribution network, cost-cutting measures, and growth plans in the CBD market, read the full report now.Report link: https://www.researchfrc.com/elixinol-wellness-limited-asx-exl-otc-ellxf-ramping-up-revenue-while-slashing-costs/
*FRC provides issuer-paid coverage.*Past performance is not indicative of future results.